Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
JANX vs NUVB: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
NUVB Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–2 Matrix Metrics)
NUVB Overall Winner
6-Pillar Tally: JANX 1 – 4 NUVB (1 Tie)
Matrix Metrics: JANX 2 – 6 NUVB
As of Nov 20, 2026, Nuvation Bio Inc. (NUVB) is the stronger overall head-to-head candidate over Janux Therapeutics, Inc. (JANX) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). JANX carries a Unified Composite Score of 50.8/100 (HOLD) at $10.08 (N/M Forward P/E, -599.3% operating margin), whereas NUVB carries 61.0/100 (BUY) at $3.80 (N/M Forward P/E, -61.2% operating margin).
- Technical & Structure Timing Caution: JANX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 25.4); meanwhile NUVB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About JANX vs NUVB
JANX
Janux Therapeutics, Inc. Common Stock
$10.08
-2.04% 1D
Market Cap
$629.6M
TTM Revenue
$23M
Forward P/E
N/M
Beta / 30D Vol
0.69β · 114% Vol
Unified Composite Score
50.8
HOLD
Tech 45.0
Fund 56.0
Flow 67.0
Mom 55.0
Weinstein Technical Phase
Markdown · Sell / avoid
NUVB
Head-to-Head Winner
Nuvation Bio Inc.
$3.80
-0.26% 1D
Market Cap
$1.3B
TTM Revenue
$202M
Forward P/E
N/M
Beta / 30D Vol
1.52β · 55% Vol
Unified Composite Score
61.0
BUY
Tech 53.0
Fund 61.0
Flow 67.0
Mom 64.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (JANX 1 – 4 NUVB)
1. Valuation Multiples
NUVB
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
26.1x
7.4x
2. Growth & Scale
NUVB
Revenue Growth (YoY)
-7.1%
+242.6%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$23M
$202M
Market Cap
$629.6M
$1.3B
3. Profitability & Quality
NUVB
Gross Margin
N/A
85.8%
Operating Margin
-599.3%
-61.2%
Net Profit Margin
0.0%
-67.4%
Return on Equity (ROE)
-10.6%
-49.1%
4. Balance Sheet & Cash Flow
JANX
Cash Generation (TTM)
-$54M
-$108M
Cash Flow Margin
N/A
-53.6%
Net Cash / Leverage
$21M Net Cash
$146M Net Debt (1.32x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
NUVB
Options Structure Phase
BREAKDOWN
BREAKDOWN
Current IV / %ile
75.4% (17th %ile)
65.2% (26th %ile)
Put/Call OI Skew
3.20x (Put-Skewed)
0.24x (Call-Skewed)
OBV Trend / Tech Phase
DISTRIBUTION · Markdown
DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: JANX (2) vs NUVB (6)| Institutional Metric | JANX | NUVB | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $629.6M | $1.3B | NUVB | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | -7.1% | +242.6% | NUVB | |
| Operating Margin (TTM) | -599.3% | -61.2% | NUVB | |
| Net Profit Margin | 0.0% | -67.4% | JANX | |
| Return on Equity (ROE) | -10.6% | -49.1% | JANX | |
| 52-Week Range Position | 0% ($10–$35) | 2% ($4–$10) | NUVB | |
| Beta / 30D Volatility | 0.69β · 114% Vol | 1.52β · 55% Vol | NUVB | |
| Unified Institutional Score | 50.8 / 100 (HOLD) | 61.0 / 100 (BUY) | NUVB | |
| Trailing 12M Revenue (USD) | $23M | $202M | Scale | |
| Gross Profit Margin (TTM) | N/A | 85.8% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 26.1x EV/Rev | N/M PEG · 7.4x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$54M ($21M Net Cash) | -$108M ($146M Net Debt (1.32x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
NUVB +21.76 pp
3M Horizon
NUVB +2.02 pp
6M Horizon
NUVB +11.09 pp
1Y Horizon
NUVB +18.16 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | JANX Revenue | NUVB Revenue | JANX Op. Margin | NUVB Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2021 | $0M | N/A | -905.4% | N/A | JANX |
| FY2022 | $10M | N/A | -779.0% | N/A | JANX |
| FY2023 | $10M | N/A | -902.9% | N/A | JANX |
| FY2024 | $10M | $10M | -933.6% | -7527.3% | JANX |
| FY2025 | $10M | $60M | -1576.7% | -338.7% | NUVB |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
JANX
BREAKDOWN
Current IV
75.4%
IV Percentile
17th %ile
Put/Call OI Skew
3.20x (Put-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
DISTRIBUTION
Exact JANX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
NUVB
BREAKDOWN
Current IV
65.2%
IV Percentile
26th %ile
Put/Call OI Skew
0.24x (Call-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact NUVB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
JANX Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
NUVB Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ JANX vs NUVB Key Questions & Quantitative Answers
As of Nov 20, 2026, Nuvation Bio Inc. (NUVB) is the stronger overall head-to-head candidate over Janux Therapeutics, Inc. (JANX) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). JANX carries a Unified Composite Score of 50.8/100 (HOLD) at $10.08 (N/M Forward P/E, -599.3% operating margin), whereas NUVB carries 61.0/100 (BUY) at $3.80 (N/M Forward P/E, -61.2% operating margin). Technical & Structure Timing Caution: JANX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 25.4); meanwhile NUVB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
NUVB leads the Growth & Scale pillar: JANX posts -7.1% YoY revenue growth and +0.0% YoY earnings growth on $23M TTM revenue (N/A gross margin, -599.3% operating margin), compared with NUVB at +242.6% YoY revenue growth and +0.0% YoY earnings growth on $202M TTM revenue (85.8% gross margin, -61.2% operating margin). Across the 5-period historical trajectory (FY2021 to FY2025), JANX cumulative revenue shifted +0.0% while NUVB shifted +500.0%. In operating R&D and SG&A reinvestment, JANX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NUVB.
NUVB screens cheaper on headline valuation multiples. JANX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 26.1x EV/Revenue (unreported FCF margin), whereas NUVB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.4x EV/Revenue (-53.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against JANX (-10.6% ROE) versus NUVB (-49.1% ROE) capital efficiency.
In options market volatility and institutional positioning, JANX carries 75.4% implied volatility (17th %ile, Compressed (<25th %ile)), a 3.20x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.69β · 114% Vol realized risk). By comparison, NUVB carries 65.2% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 0.24x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.52β · 55% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
NUVB vs JANX · Reverse Pair
JANX vs VERA
· Sector Peer
JANX vs EWTX
· Sector Peer
JANX vs FDMT
· Sector Peer
NUVB vs LYEL
· Sector Peer
NUVB vs TSHA
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem